Protective autophagy elicited by RAF→ MEK→ ERK inhibition suggests a treatment strategy for RAS-driven cancers
CG Kinsey, SA Camolotto, AM Boespflug, KP Guillen… - Nature medicine, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDA) was responsible for~ 44,000 deaths in the United
States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically …
States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically …
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS-and autophagy-
dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been …
dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been …
Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma
OK Mirzoeva, B Hann, YK Hom, J Debnath… - Journal of molecular …, 2011 - Springer
Targeting of pathways downstream of RAS represents a promising therapeutic strategy for
pancreatic cancer, the fourth leading cause of cancer-related death in the USA, since …
pancreatic cancer, the fourth leading cause of cancer-related death in the USA, since …
Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors
CA Stalnecker, KR Grover, AC Edwards, MF Coleman… - Cancer research, 2022 - AACR
The aggressive nature of pancreatic ductal adenocarcinoma (PDAC) mandates the
development of improved therapies. As KRAS mutations are found in 95% of PDAC and are …
development of improved therapies. As KRAS mutations are found in 95% of PDAC and are …
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western
countries, with a median survival of 6 months and an extremely low percentage of long-term …
countries, with a median survival of 6 months and an extremely low percentage of long-term …
[HTML][HTML] Targeting autophagy addiction in cancer
JD Mancias, AC Kimmelman - Oncotarget, 2011 - ncbi.nlm.nih.gov
Autophagy inhibition is a novel cancer therapeutic strategy in the early stages of clinical trial
testing. The initial rationale for using autophagy inhibition was generated by research …
testing. The initial rationale for using autophagy inhibition was generated by research …
Regulation and function of autophagy in pancreatic cancer
Oncogenic KRAS mutation-driven pancreatic ductal adenocarcinoma is currently the fourth-
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Autophagy is a catabolic pathway used by cells to support metabolism in response to
starvation and to clear damaged proteins and organelles in response to stress. We report …
starvation and to clear damaged proteins and organelles in response to stress. We report …
[HTML][HTML] KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism
AV Vaseva, DR Blake, TSK Gilbert, S Ng, G Hostetter… - Cancer cell, 2018 - cell.com
Our recent ERK1/2 inhibitor analyses in pancreatic ductal adenocarcinoma (PDAC)
indicated ERK1/2-independent mechanisms maintaining MYC protein stability. To identify …
indicated ERK1/2-independent mechanisms maintaining MYC protein stability. To identify …
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
CH Eng, Z Wang, D Tkach… - Proceedings of the …, 2016 - National Acad Sciences
Macroautophagy is a key stress-response pathway that can suppress or promote
tumorigenesis depending on the cellular context. Notably, Kirsten rat sarcoma (KRAS) …
tumorigenesis depending on the cellular context. Notably, Kirsten rat sarcoma (KRAS) …